ArticleJournal of the Canadian Association of Gastroenterology2024

Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.

Cheng-Chun Tai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.